BeiGene
BGNE
#934
Rank
A$32.61 B
Marketcap
$293.13
Share price
-2.10%
Change (1 day)
-2.88%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$25.02

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$25.78. In 2022 the company made an earnings per share (EPS) of -$30.01 a decrease over its 2021 EPS that were of -$23.56.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$25.02-16.62%
2022-$30.0127.35%
2021-$23.56-19.96%
2020-$29.4420.81%
2019-$24.3731.52%
2018-$18.53417.57%
2017-$3.58-37.16%
2016-$5.70158.95%
2015-$2.20

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.55-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.42-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA